

**Ohio Department of Medicaid (ODM)  
Drug Utilization Review (DUR) Board  
Quarterly Meeting  
September 15, 2015**

The quarterly meeting of the ODM DUR Board was called to order at 12:00 PM in room East B on the 31st Floor of the Riffe Center, 77 S. High Street, Columbus, Ohio. Michael Farrell, MD, presided. The following Board members were present:

Michael Farrell, MD, Chair  
Thomas Gretter, MD  
Robert Kubasak, RPh  
J. Layne Moore, MD  
Lenard Presutti, DO

Also present from ODM were: Margaret Scott, RPh, DUR Administrator; Jill Griffith, RPh, DUR Director; Patti Nussle, RPh. Pam Heaton, RPh, PhD represented the University Of Cincinnati. Approximately 20 observers were present, most representatives of pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The May 19<sup>th</sup>, 2015, DUR Board minutes were approved. (1<sup>st</sup> T. Gretter, 2<sup>nd</sup> L. Presutti).

Health Plan Policy:

M. Scott updated the Board on the new pharmacy benefits manager that has been selected to process claims and prior authorizations for the fee-for-service (FFS) population, manage the preferred drug list (PDL), handle rebates, and assist ODM with program oversight and reporting. Goold Health Systems (GHS) has been awarded the contract. Clinical services including the PDL will begin in October, with claims processing and other services to transition in the spring. Jill Griffith has begun work with GHS as the Account Manager so has left the DUR Director position with ODM.

In future meetings, GHS will present prospective DUR criteria for the Board's review. Discussion ensued regarding appropriate prospective edits to be used in the new claims system.

DUR Committee Report:

In June, the DUR Committee continued to review patients with high morphine equivalent doses (MED), with letters mailed in July. The Committee also reviewed profiles for patients with developmental disabilities who received psychotropic medications without a mental health diagnosis and mailed letters to prescribers in July. Letters regarding patients on multiple daily doses of Abilify were mailed on June 1.

In July, the Committee re-reviewed patient using high numbers of rescue inhalers. M. Farrell noted that many children require two inhalers to be dispensed at a time because they have multiple homes.

In August, the Committee re-reviewed patients with duplicate long-acting opioids and continued watching patients with high MEDs.

In September, the Committee re-reviewed patients with concurrent insulin and sulfonylurea prescriptions.

Unfinished Business:

M. Scott updated the Board on The Governor's Cabinet Opiate Action Team. The group has completed guidelines for acute pain prescribing, and asked stakeholder groups to endorse the guidelines. M. Farrell noted that the American Academy of Pediatrics has published a strong statement against the use of codeine in children.

Announcements:

The fourth quarter meeting will be held on November 17<sup>th</sup>, 2015.

Adjournment:

M. Farrell adjourned the meeting at 12:34 PM.

Respectfully submitted:

---

Margaret Scott, RPh, DUR Administrator